Chui Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chui Zeng has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Jianrui Wei
Department of Cardiac Center, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University
2 shared publications - Wenqian Cai
Heart Centre and Institute of Paediatrics, Guangzhou Women and Children's Medical Center Guangzhou Medical University Guangzhou China
2 shared publications Dacai Xu
Heart Center and Institute of Pediatrics (W.C., D.X., C.Z., R.L., Y.L., Y.Z., W.D., Q.W., D.W., J.G., J.W., J.D.), Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, China
1 shared publicationDaqiang Wen
Heart Center and Institute of Pediatrics (W.C., D.X., C.Z., R.L., Y.L., Y.Z., W.D., Q.W., D.W., J.G., J.W., J.D.), Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, China
1 shared publication- Dongmei Sun
Pingdi Public Health Service Center, Longgang District, Shenzhen 518117, China
1 shared publication Fan Liao
School of Medicine‚ South China University of Technology, Guangzhou (F.L., J.D.).
1 shared publication
Latest Publications
- 29 December 2025
- Published by Wiley in The FASEB Journal
- Vol. 40 (1) , e71378
Spatial Metabolomics Reveals GLA ‐Mediated Imbalance of Gal 2 Cer / GalCer as a Therapeutic Target in Myocardial Ischemia–Reperfusion Injury
Myocardial ischemia–reperfusion (I/R) injury, a major complication of reperfusion therapies for acute myocardial infarction that exacerbates myocardial necrosis, impairs cardiac function, and worsens patient prognosis. Profound metabolic disturbances drive myocardial I/R injury; however, their spatial heterogeneity remains unclear. Using MALDI mass spectrometry imaging with spatial segmentation, we mapped the spatiotemporal metabolite dynamics in mouse heart tissue across multiple time points (30 min ischemia to 7 days reperfusion), aiming to identify critical metabolic pathways and regulatory targets underlying I/R injury. Glycerophospholipids and sphingolipids exhibited pronounced heterogeneity. Glycerophospholipid metabolism remained dysregulated throughout the I/R process, with long‐chain phospholipids (PA, PE, PC, and PS) exhibiting a distinct distribution gradient. They were enriched in the remote zone, downregulated in the border zone, and markedly reduced in the injured zone 6 h post‐reperfusion. Sphingolipid metabolism was dynamically reprogrammed, with galactosylceramide (GalCer) accumulating and digalactosylceramide (Gal 2 Cer) depleting in injured and border zones. Mechanistically, α‐galactosidase (GLA), which hydrolyzes Gal2Cer to GalCer, was upregulated in the border zone post‐I/R. Functional validation further demonstrated that both cardiomyocyte‐specific GLA knockdown (via AAV‐shGla) and pharmacological inhibition (using the GLA inhibitor GR181413A) effectively reduced myocardial infarct size, alleviated pathological remodeling, and improved cardiac function in I/R‐injured mice. Collectively, our spatial metabolomics revealed that GLA‐mediated Gal2Cer/GalCer imbalance is a critical regulator of myocardial I/R injury, and targeting GLA represents a promising therapeutic strategy.
- 29 December 2025
- Published by Wiley in The FASEB Journal
- Vol. 40 (1) , e71378
Spatial Metabolomics Reveals GLA ‐Mediated Imbalance of Gal 2 Cer / GalCer as a Therapeutic Target in Myocardial Ischemia–Reperfusion Injury
Myocardial ischemia–reperfusion (I/R) injury, a major complication of reperfusion therapies for acute myocardial infarction that exacerbates myocardial necrosis, impairs cardiac function, and worsens patient prognosis. Profound metabolic disturbances drive myocardial I/R injury; however, their spatial heterogeneity remains unclear. Using MALDI mass spectrometry imaging with spatial segmentation, we mapped the spatiotemporal metabolite dynamics in mouse heart tissue across multiple time points (30 min ischemia to 7 days reperfusion), aiming to identify critical metabolic pathways and regulatory targets underlying I/R injury. Glycerophospholipids and sphingolipids exhibited pronounced heterogeneity. Glycerophospholipid metabolism remained dysregulated throughout the I/R process, with long‐chain phospholipids (PA, PE, PC, and PS) exhibiting a distinct distribution gradient. They were enriched in the remote zone, downregulated in the border zone, and markedly reduced in the injured zone 6 h post‐reperfusion. Sphingolipid metabolism was dynamically reprogrammed, with galactosylceramide (GalCer) accumulating and digalactosylceramide (Gal 2 Cer) depleting in injured and border zones. Mechanistically, α‐galactosidase (GLA), which hydrolyzes Gal2Cer to GalCer, was upregulated in the border zone post‐I/R. Functional validation further demonstrated that both cardiomyocyte‐specific GLA knockdown (via AAV‐shGla) and pharmacological inhibition (using the GLA inhibitor GR181413A) effectively reduced myocardial infarct size, alleviated pathological remodeling, and improved cardiac function in I/R‐injured mice. Collectively, our spatial metabolomics revealed that GLA‐mediated Gal2Cer/GalCer imbalance is a critical regulator of myocardial I/R injury, and targeting GLA represents a promising therapeutic strategy.
- Open Access
The Intrinsic Innate Immunity of Hepatocytes Suppresses HBV Replication and Is Antagonized by HBx
(1) Background: Hepatitis B virus (HBV) belongs to the Hepadnaviridae family of viruses that interact with hepatocytes. HBV infection is a major global health problem. Most adults clear the infection quickly after being infected with HBV, while a few people develop chronic HBV infection. It is well-known that the early innate immune response of host cells plays an important role in the fight against virus infection. However, the interactions between HBV and the intrinsic innate immune system of hepatocytes are still not fully understood. The aim of this study was to confirm the interaction between HBV and hepatocytes, and to identify the interferon-stimulated genes (ISGs) regulated by HBx and their expression in association with HBV-associated HCC (HBV-HCC), so that we can refine our understanding of the interaction between HBV and ISGs and its potential influence on HBV-HCC. (2) Methods: We analyzed data concerning the stimulation of IFN-dependent genes in primary human hepatocytes (PHHs) transfected with pathogen DNA mimetics or infected with HBV in the GSE69590 database. Bioinformatic methods, such as GSEA, GO, and KEGG, were used to analyze the differentially expressed innate immunity genes and their related pathways to identify candidate intrinsic innate immune factors. qPCR on HepG2 and Huh7 cells, which highly express HBx, was used to detect relevant intrinsic innate immune factors. qPCR, RNAi, and Elisa methods were used to identify intrinsic innate immune factors in HBV-integrated HepG2.2.15 cells, and bioinformatics analysis was conducted on the HBV-infected tissues and cells in the GEO database. (3) Results: Inhibition of the JAK-STAT pathway enhanced HBV replication in HepG2 cells transfected with HBV plasmid and HepG2-NTCP cells infected with HBV. GSEA analysis of the GSE69590 data revealed significant changes in intrinsic innate immune pathways during HBV infection with PHH for 40 h. A total of 84 differentially expressed, candidate innate immunity genes were identified in GSE69590. Validation showed that TRIM22 and TRIM56 were down-regulated when HBx was expressed. Consistently, TRIM22 and TRIM56 were up-regulated following inhibition of HBx by transfection of HBx siRNA into HepG2.2.15 cells, and HBV pgRNA was up-regulated following down-regulated expression of TRIM22 and TRIM56 in HEK293 cells. Receiver operating characteristics (ROC) and overall survival (OS) analysis of 204 HBV-HCC patients showed that expression of TRIM22 was closely associated with HBV-HCC, and high expression of TRIM22 was associated with longer survival. (4) Conclusions: Innate immunity genes TRIM22 and TRIM56 are regulated by HBx, and higher expression of TRIM22 is closely related to longer survival of HBV-HCC patients.
Open AccessThe Intrinsic Innate Immunity of Hepatocytes Suppresses HBV Replication and Is Antagonized by HBx
(1) Background: Hepatitis B virus (HBV) belongs to the Hepadnaviridae family of viruses that interact with hepatocytes. HBV infection is a major global health problem. Most adults clear the infection quickly after being infected with HBV, while a few people develop chronic HBV infection. It is well-known that the early innate immune response of host cells plays an important role in the fight against virus infection. However, the interactions between HBV and the intrinsic innate immune system of hepatocytes are still not fully understood. The aim of this study was to confirm the interaction between HBV and hepatocytes, and to identify the interferon-stimulated genes (ISGs) regulated by HBx and their expression in association with HBV-associated HCC (HBV-HCC), so that we can refine our understanding of the interaction between HBV and ISGs and its potential influence on HBV-HCC. (2) Methods: We analyzed data concerning the stimulation of IFN-dependent genes in primary human hepatocytes (PHHs) transfected with pathogen DNA mimetics or infected with HBV in the GSE69590 database. Bioinformatic methods, such as GSEA, GO, and KEGG, were used to analyze the differentially expressed innate immunity genes and their related pathways to identify candidate intrinsic innate immune factors. qPCR on HepG2 and Huh7 cells, which highly express HBx, was used to detect relevant intrinsic innate immune factors. qPCR, RNAi, and Elisa methods were used to identify intrinsic innate immune factors in HBV-integrated HepG2.2.15 cells, and bioinformatics analysis was conducted on the HBV-infected tissues and cells in the GEO database. (3) Results: Inhibition of the JAK-STAT pathway enhanced HBV replication in HepG2 cells transfected with HBV plasmid and HepG2-NTCP cells infected with HBV. GSEA analysis of the GSE69590 data revealed significant changes in intrinsic innate immune pathways during HBV infection with PHH for 40 h. A total of 84 differentially expressed, candidate innate immunity genes were identified in GSE69590. Validation showed that TRIM22 and TRIM56 were down-regulated when HBx was expressed. Consistently, TRIM22 and TRIM56 were up-regulated following inhibition of HBx by transfection of HBx siRNA into HepG2.2.15 cells, and HBV pgRNA was up-regulated following down-regulated expression of TRIM22 and TRIM56 in HEK293 cells. Receiver operating characteristics (ROC) and overall survival (OS) analysis of 204 HBV-HCC patients showed that expression of TRIM22 was closely associated with HBV-HCC, and high expression of TRIM22 was associated with longer survival. (4) Conclusions: Innate immunity genes TRIM22 and TRIM56 are regulated by HBx, and higher expression of TRIM22 is closely related to longer survival of HBV-HCC patients.
- 19 August 2022
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 131 (5) , 456-472
Modulating Lysine Crotonylation in Cardiomyocytes Improves Myocardial Outcomes
Background: Ischemic heart disease is a major global public health challenge, and its functional outcomes remain poor. Lysine crotonylation (Kcr) was recently identified as a post-translational histone modification that robustly indicates active promoters. However, the role of Kcr in myocardial injury is unknown. In this study, we aimed to clarify the pathophysiological significance of Kcr in cardiac injury and explore the underlying mechanism. Methods: We investigated the dynamic change of both the Kcr sites and protein level in left ventricular tissues at 2 time points following sham or cardiac ischemia-reperfusion injury, followed by liquid chromatography-coupled tandem mass tag mass spectrometry. After validation of the enriched protein Kcr by immunoprecipitation and Western blot, the function and mechanism of specific Kcr sites were further investigated in vitro and in vivo by gain- or loss-of-function mutations targeting Kcr sites of selected proteins. Results: We found that cardiac ischemia-reperfusion injury triggers preferential Kcr of proteins required for cardiomyocyte contractility, including mitochondrial and cytoskeleton proteins, which occurs largely independently of protein-level changes in the same proteins. Those exhibiting Kcr changes were associated not only with disruption of cardiomyocyte mitochondrial, sarcomere architecture, and gap junction but also with cardiomyocyte autophagy and apoptosis. Modulating site-specific Kcr of selected mitochondrial protein IDH3a (isocitrate dehydrogenase 3 [NAD+] alpha) at K199 and cytoskeletal protein TPM1 (tropomyosin alpha-1 chain) at K28/29 or enhancing general Kcr via sodium crotonate provision not only protects cardiomyocyte from apoptosis by inhibiting BNIP3 (Bcl-2 adenovirus E18 19-kDa–interacting protein 3)-mediated mitophagy or cytoskeleton structure rearrangement but also preserves postinjury myocardial function by inhibiting fibrosis and apoptosis. Conclusions: Our results indicate that Kcr modulation is a key response of cardiomyocytes to ischemia-reperfusion injury and may represent a novel therapeutic target in the context of ischemic heart disease.
- 19 August 2022
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 131 (5) , 456-472
Modulating Lysine Crotonylation in Cardiomyocytes Improves Myocardial Outcomes
Background: Ischemic heart disease is a major global public health challenge, and its functional outcomes remain poor. Lysine crotonylation (Kcr) was recently identified as a post-translational histone modification that robustly indicates active promoters. However, the role of Kcr in myocardial injury is unknown. In this study, we aimed to clarify the pathophysiological significance of Kcr in cardiac injury and explore the underlying mechanism. Methods: We investigated the dynamic change of both the Kcr sites and protein level in left ventricular tissues at 2 time points following sham or cardiac ischemia-reperfusion injury, followed by liquid chromatography-coupled tandem mass tag mass spectrometry. After validation of the enriched protein Kcr by immunoprecipitation and Western blot, the function and mechanism of specific Kcr sites were further investigated in vitro and in vivo by gain- or loss-of-function mutations targeting Kcr sites of selected proteins. Results: We found that cardiac ischemia-reperfusion injury triggers preferential Kcr of proteins required for cardiomyocyte contractility, including mitochondrial and cytoskeleton proteins, which occurs largely independently of protein-level changes in the same proteins. Those exhibiting Kcr changes were associated not only with disruption of cardiomyocyte mitochondrial, sarcomere architecture, and gap junction but also with cardiomyocyte autophagy and apoptosis. Modulating site-specific Kcr of selected mitochondrial protein IDH3a (isocitrate dehydrogenase 3 [NAD+] alpha) at K199 and cytoskeletal protein TPM1 (tropomyosin alpha-1 chain) at K28/29 or enhancing general Kcr via sodium crotonate provision not only protects cardiomyocyte from apoptosis by inhibiting BNIP3 (Bcl-2 adenovirus E18 19-kDa–interacting protein 3)-mediated mitophagy or cytoskeleton structure rearrangement but also preserves postinjury myocardial function by inhibiting fibrosis and apoptosis. Conclusions: Our results indicate that Kcr modulation is a key response of cardiomyocytes to ischemia-reperfusion injury and may represent a novel therapeutic target in the context of ischemic heart disease.